Capricor Therapeutics Inc  

(Public, NASDAQ:CAPR)   Watch this stock  
Find more results for CAPR
-0.09 (-4.77%)
Real-time:   12:33PM EST
NASDAQ real-time data - Disclaimer
Currency in USD
Range 1.70 - 1.83
52 week 0.63 - 4.25
Open 1.81
Vol / Avg. 431,326.00/724,216.00
Mkt cap 45.30M
P/E     -
Div/yield     -
EPS -0.66
Shares 25.71M
Beta -4.66
Inst. own 9%
Mar 13, 2018
Q4 2017 Capricor Therapeutics Inc Earnings Release (Estimated) Add to calendar
More events from DailyFinance »    

Key stats and ratios

Q3 (Sep '17) 2016
Net profit margin -873.05% -470.33%
Operating margin -842.00% -462.07%
EBITD margin - -421.19%
Return on average assets -73.10% -108.03%
Return on average equity - -
Employees 29 -
CDP Score - -


8840 Wilshire Blvd Fl 2
BEVERLY HILLS, CA 90211-2606
United States - Map
+1-310-3583200 (Phone)
+1-302-6555049 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


Capricor Therapeutics, Inc. is a clinical-stage biotechnology company focused on the discovery, development and commercialization of therapeutics. The Company focuses on discovering, developing and commercializing regenerative medicine and large molecule products for the treatment of disease, with a primary focus on the treatment of cardiovascular diseases, including orphan indications. Its product candidate, CAP-1002, a cardiosphere-derived cell product, is being tested in the ALLSTAR Phase II clinical study on patients having suffered a myocardial infarction (MI), while the DYNAMIC clinical study is testing CAP-1002 in patients in the advanced-stage of heart failure. CAP-1002 is also being tested in the HOPE-Duchenne Phase I/II clinical study for use in connection with Duchenne muscular dystrophy-related cardiomyopathy. Cenderitide, a dual receptor natriuretic peptide agonist, is being tested in a Phase II clinical study. Exosomes are nano-sized, membrane-enclosed vesicles.

Officers and directors

Frank I. Litvack M.D. Independent Executive Chairman of the Board
Age: 59
Bio & Compensation  - Reuters
Linda Marban Ph.D. President, Chief Executive Officer, Director
Age: 51
Bio & Compensation  - Reuters
Anthony Bergmann Chief Financial Officer, Principal Accounting Officer
Age: 32
Bio & Compensation  - Reuters
Karen G. Krasney J.D. Executive Vice President, General Counsel
Age: 62
Bio & Compensation  - Reuters
Thomas Lyle Copmann Ph.D. Vice President - Regulatory Affairs and Drug Development
Age: 61
Bio & Compensation  - Reuters
Houman Hemmati M.D., Ph.D. Vice President - Medical & Clinical Development, New Therapies
Bio & Compensation  - Reuters
Luis Rodriguez-Borlado Ph.D. Vice President - Regenerative Therapies
Bio & Compensation  - Reuters
Rachel Smith Ph.D. Vice President - Research & Development
Age: 36
Bio & Compensation  - Reuters
Deborah Ascheim M.D. Chief Medical Officer
Bio & Compensation  - Reuters
Joshua A. Kazam Director
Age: 40
Bio & Compensation  - Reuters